My watch list  


Companies Sepsis

Molzym GmbH & Co. KG, Germany

Company Molzym was founded as a privately owned enterprise in Bremen, North-West Germany, in 2003. Ever since its foundation, Molzym was committed to develop innovative solutions to serve biological research and diagnosis of infectious diseases. Products range from pre-analytical kits for the enric more

Products Sepsis

Culture-Independent Diagnosis of Bacterial and Fungal DNA in Blood, Other Body Fluids and Tissues

Culture-independent, CE IVD-marked diagnosis of pathogens of 200 bacterial and 65 fungal genera in tissue biopsies, blood and other body fluids more

Direct PCR-based identification of bacteraemia and fungaemia in antibiotic-treated patients

Using CE IVD SepsiTest™ highly enriched microbial DNA is provided to universal PCR analysis. This results in ultra-sensitive pathogen identification more

News Sepsis

  • Study ends debate over role of steroids in treating septic shock

    The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year. Researchers at The George Institute for Global Health studied whether the use of steroids as an additional treatmen more

  • Symcel secures €3.6 million Horizon 2020 Phase II grant

    Symcel, the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™, has secured €3.572 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria more

  • Unlocking the secrets of Ebola

    Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease. The results come from scientists at the Department of Energy's Pacific Northwest National Laboratory and their colleagues at the University of Wiscons more

All news on sepsis

White papers Sepsis

Events Sepsis


Application of DSC to structural studies on meningitis vaccines

Neisseria meningitidis is the leading cause of bacteraemia and sepsis in children and young adults due to the non-specific nature of the initial symptoms and rapid progress of the infection. Vaccination is the best approach to protect individuals and progress has been made in their development. Howe

Publications Sepsis

All publications on sepsis

Market studies Sepsis

  • Sepsis – Pipeline Review, H1 2012

    Introduction Global Markets Direct’s, 'Sepsis - Pipeline Review, H1 2012', provides an overview of the Sepsis therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects more

  • Sepsis Global Clinical Trials Review, Q2, 2011

    Introduction GlobalData's clinical trial report, “Sepsis Global Clinical Trials Review, Q2, 2011" provides data on the Sepsis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sepsis. It includes an overview of the trial numbers and thei more

  • Sepsis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Introduction GlobalData, the industry analysis specialist, has released its new report, “Sepsis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Sepsis Therapeutics market. The report identifies the key tre more

All market studies on sepsis


Sepsis Sepsis is a serious medical condition characterized by a whole-body inflammatory state caused by infection . Traditionally the term sepsis has been used interchangeably with septicaemia/septicemia ("blood poisoning "). However, these t ... more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE